Tempest Therapeutics Files 424B3 Prospectus
Ticker: TPST · Form: 424B3 · Filed: 2026-04-10T09:25:54-04:00
Sentiment: neutral
Topics: prospectus, securities-offering, filing
TL;DR
Tempest Therapeutics just dropped a prospectus (424B3) - looks like they're selling more stock.
AI Summary
Tempest Therapeutics, Inc. filed a 424B3 prospectus on April 10, 2026, detailing its securities offering. The filing provides information for investors regarding the company's offerings, with its principal executive offices located at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005.
Why It Matters
This filing is a prospectus, which means Tempest Therapeutics is likely offering new securities to the public, potentially impacting its stock price and capital structure.
Risk Assessment
Risk Level: medium — A 424B3 filing indicates a securities offering, which carries inherent risks for investors related to market volatility and company performance.
Key Numbers
- 424B3 — Form Type (Indicates a prospectus filing for securities offerings)
- 0001193125-26-150470 — Accession Number (Unique identifier for the SEC filing)
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Filer of the prospectus
- 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005 (location) — Company's business and mailing address
- 0001544227 (company_id) — CIK number for Tempest Therapeutics, Inc.
- 2026-04-10 (date) — Filing date of the 424B3 prospectus
FAQ
What type of securities is Tempest Therapeutics offering in this prospectus?
The filing is a 424B3 prospectus, which is used to register securities for sale. Specific details on the type and amount of securities would be found within the prospectus document itself.
What is the purpose of a 424B3 filing?
A 424B3 filing is a prospectus that supplements a registration statement and is used to offer securities to the public.
When was this prospectus filed with the SEC?
This prospectus was filed on April 10, 2026.
Where are Tempest Therapeutics' principal offices located?
Tempest Therapeutics' principal offices are located at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005.
What is the CIK number for Tempest Therapeutics, Inc.?
The CIK number for Tempest Therapeutics, Inc. is 0001544227.
From the Filing
EDGAR Filing Documents for 0001193125-26-150470 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 424B3 - Prospectus [Rule 424(b)(3)]: SEC Accession No. 0001193125-26-150470 Filing Date 2026-04-10 Accepted 2026-04-10 09:25:54 Documents 2 Document Format Files Seq Description Document Type Size 1 424B3 d17525d424b3.htm 424B3 82861 2 GRAPHIC g17525g16a26.jpg GRAPHIC 32146 Complete submission text file 0001193125-26-150470.txt 121873 Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589 Tempest Therapeutics, Inc. (Filer) CIK : 0001544227 (see all company filings) EIN. : 451472564 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 424B3 | Act: 33 | File No.: 333-294843 | Film No.: 26853370 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)